Shahid Husain1, Mariangela R Resende, Nimerta Rajwans, Ricardo Zamel, Joseph M Pilewski, Maria M Crespo, Lianne G Singer, Kenneth R McCurry, Jay K Kolls, Shaf Keshavjee, W Conrad Liles. 1. 1 Division of Infectious Diseases, Department of Medicine, Multi-Organ Transplant Institute, University Health Network, University of Toronto, Toronto, Ontario, Canada. 2 Division of Infectious Diseases, Department of Medicine, Toronto General Research Institute, McLaughlin-Rotman Centre for Global Health, McLaughlin Centre for Molecular Medicine, University Health Network, University of Toronto, Toronto, Ontario, Canada. 3 The Toronto Lung Transplant Program, McEwen Centre for Regenerative Medicine, Toronto General Research Institute, University Health Network, University of Toronto, Toronto, Ontario, Canada. 4 Division of Pulmonary, Allergy, and Critical Care Medicine, Department of Medicine, University of Pittsburgh, Pittsburgh, PA. 5 Division of Respirology, Department of Medicine, The Toronto Lung Transplant Program, University Health Network, University of Toronto, Toronto, Ontario, Canada. 6 Department of Cardiothoracic Surgery, Cleveland Clinic, Cleveland, OH. 7 Departments of Pediatrics and Immunology, University of Pittsburgh, Pittsburgh, PA. 8 Department of Medicine, University of Washington, Seattle, WA. 9 Address correspondence to: Shahid Husain, M.D., M.S., Division of Infectious Diseases, Department of Medicine, Multi-Organ Transplant Institute, University Health Network, University of Toronto, Toronto, Ontario, Canada.
Abstract
BACKGROUND: CXCL10 (IP-10) is a potent chemoattractant for T cells that has been postulated to play a role in infection and acute cellular rejection (ACR) in animal models. We measured CXCL10 (IP-10) (and other cytokines previously implicated in the pathogenesis of ACR) in the bronchoalveolar lavage (BAL) of lung transplant recipients (LTRs) to determine the association between CXCL10 (IP-10) and ACR in LTRs. METHODS: In a prospective study of 85 LTRs, expression of cytokines (tumor necrosis factor, interferon-γ, interleukin [IL]-6, IL-8, IL-15, IL-16, IL-17, CXCL10 [IP-10], and MCP-1 [CCL2]) in BAL samples (n=233) from patients with episodes of ACR (n=44), infection ("Infect"; n=25), concomitant "Infect+ACR" (n=10), and "No Infect and No ACR" (n=154) were analyzed. RESULTS: The levels of both CXCL10 (IP-10) and IL-16 were significantly increased in histologically proven ACR compared with the "No Infect and No ACR" group (CXCL10 [IP-10]: 107.0 vs. 31.9 pg/mL [P=0.001] and IL-16: 472.1 vs. 283.01 pg/mL [P=0.01]). However, in a linear mixed-effects model, significant association was found only between CXCL10 (IP-10) and ACR. A one-log increase of CXCL10 (IP-10) was associated with a 40% higher risk of ACR (odds ratio, 1.4; 95% confidence interval, 1.12-1.84). CONCLUSION: Higher values of CXCL10 (IP-10) in BAL fluid are associated with ACR in LTRs, suggesting a potential mechanistic role in the pathogenesis of ACR in LTRs. These results suggest that therapeutic strategies to inhibit CXCL10 (IP-10) and or its cognate receptor, CXCR3, warrant investigation to prevent and/or treat ACR in clinical lung transplantation.
BACKGROUND:CXCL10 (IP-10) is a potent chemoattractant for T cells that has been postulated to play a role in infection and acute cellular rejection (ACR) in animal models. We measured CXCL10 (IP-10) (and other cytokines previously implicated in the pathogenesis of ACR) in the bronchoalveolar lavage (BAL) of lung transplant recipients (LTRs) to determine the association between CXCL10 (IP-10) and ACR in LTRs. METHODS: In a prospective study of 85 LTRs, expression of cytokines (tumor necrosis factor, interferon-γ, interleukin [IL]-6, IL-8, IL-15, IL-16, IL-17, CXCL10 [IP-10], and MCP-1 [CCL2]) in BAL samples (n=233) from patients with episodes of ACR (n=44), infection ("Infect"; n=25), concomitant "Infect+ACR" (n=10), and "No Infect and No ACR" (n=154) were analyzed. RESULTS: The levels of both CXCL10 (IP-10) and IL-16 were significantly increased in histologically proven ACR compared with the "No Infect and No ACR" group (CXCL10 [IP-10]: 107.0 vs. 31.9 pg/mL [P=0.001] and IL-16: 472.1 vs. 283.01 pg/mL [P=0.01]). However, in a linear mixed-effects model, significant association was found only between CXCL10 (IP-10) and ACR. A one-log increase of CXCL10 (IP-10) was associated with a 40% higher risk of ACR (odds ratio, 1.4; 95% confidence interval, 1.12-1.84). CONCLUSION: Higher values of CXCL10 (IP-10) in BAL fluid are associated with ACR in LTRs, suggesting a potential mechanistic role in the pathogenesis of ACR in LTRs. These results suggest that therapeutic strategies to inhibit CXCL10 (IP-10) and or its cognate receptor, CXCR3, warrant investigation to prevent and/or treat ACR in clinical lung transplantation.
Authors: John A Belperio; Michael P Keane; Marie D Burdick; Joseph P Lynch; David A Zisman; Ying Ying Xue; Kewang Li; Abbas Ardehali; David J Ross; Robert M Strieter Journal: J Immunol Date: 2003-11-01 Impact factor: 5.422
Authors: E Rondeau; J Cerrina; F Delarue; F L Ladurie; P Herve; A Chapelier; P Dartevelle; J D Sraer Journal: Transplant Proc Date: 1990-08 Impact factor: 1.066
Authors: M Rizzo; K S SivaSai; M A Smith; E P Trulock; J P Lynch; G A Patterson; T Mohanakumar Journal: J Heart Lung Transplant Date: 2000-09 Impact factor: 10.247
Authors: C Agostini; F Calabrese; F Rea; M Facco; A Tosoni; M Loy; G Binotto; M Valente; L Trentin; G Semenzato Journal: Am J Pathol Date: 2001-05 Impact factor: 4.307
Authors: John A Belperio; Michael P Keane; Marie D Burdick; Joseph P Lynch; Ying Ying Xue; Kewang Li; David J Ross; Robert M Strieter Journal: J Immunol Date: 2002-07-15 Impact factor: 5.422
Authors: Steve Oghumu; Uday Nori; Anna Bracewell; Jianying Zhang; Cherri Bott; Gyongyi M Nadasdy; Sergey V Brodsky; Ronald Pelletier; Abhay R Satoskar; Tibor Nadasdy; Anjali A Satoskar Journal: Clin Transplant Date: 2016-08-08 Impact factor: 2.863
Authors: Marc Hartert; Omer Senbaklavacin; Bernhard Gohrbandt; Berthold M Fischer; Roland Buhl; Christian-Friedrich Vahld Journal: Dtsch Arztebl Int Date: 2014-02-14 Impact factor: 5.594
Authors: Jennifer Mildenberger; Ida Johansson; Ismail Sergin; Eli Kjøbli; Jan Kristian Damås; Babak Razani; Trude Helen Flo; Geir Bjørkøy Journal: Autophagy Date: 2017-08-18 Impact factor: 16.016
Authors: Michael Y Shino; Jamie L Todd; Megan L Neely; Jerry Kirchner; Courtney W Frankel; Laurie D Snyder; Elizabeth N Pavlisko; Gregory A Fishbein; Joanna M Schaenman; Kristen Mason; Karen Kesler; Tereza Martinu; Lianne G Singer; Wayne Tsuang; Marie Budev; Pali D Shah; John M Reynolds; Nikki Williams; Mark A Robien; Scott M Palmer; S Sam Weigt; John A Belperio Journal: Am J Transplant Date: 2022-06-15 Impact factor: 9.369
Authors: Nicole E Speck; Elisabeth Probst-Müller; Sarah R Haile; Christian Benden; Malcolm Kohler; Lars C Huber; Cécile A Robinson Journal: Cytokine Date: 2019-08-07 Impact factor: 3.861